Showing 931-940 of 1119 results for "".
- Lumenis Acquires Pollogen and Expands its Aesthetic Divisionhttps://practicaldermatology.com/news/lumenis-acquires-pollogen-and-expands-its-aesthetic-division/2458827/Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applic
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- Report Predicts Growth in Global Dermatology Diagnostic Devices Market 2015-2019https://practicaldermatology.com/news/report-predicts-growth-in-global-dermatology-diagnostic-devices-market-2015-2019/2458869/A recently published report, Global Dermatology Diagnostic Devices Market 2015-2019, which was prepared based on an in-depth market analysis with inputs from industry experts
- Cynosure to Host Investor Event to Introduce SculpSurehttps://practicaldermatology.com/news/cynosure-to-host-investor-event-to-introduce-sculpsure/2458877/Cynosure, Inc. will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure™, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i
- FDA Approves Odomzo for Locally Advanced BCChttps://practicaldermatology.com/news/fda-approves-odomzo-sonidegib-for-locally-advanced-bcc/2458903/The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radi